During the corresponding time, Zevra Therapeutics Inc recorded a revenue increase by 53.25 % year on year, sequentially revenue grew by 36.75 %. While revenue at the Zevra Therapeutics Inc 's corporate clients
Zevra Therapeutics Inc's Comment on Sales, Marketing and Customers
The company markets several therapies targeting specific medical conditions and faces competition from various branded and generic products. MIPLYFFA, approved for Niemann-Pick disease type C (NPC), competes with AQNEURSA marketed by IntraBio, Inc., as well as drug candidates adrabetadex from Mandos and cyclodextrin from Cyclo Therapeutics. OLPRUVA competes against phenylbutyrate products including RAVICTI (Amgen Inc.), PHEBURANE (Medunik USA), and authorized generics by Par and Lupin. KP1077 is positioned to compete with XYWAV (Jazz Pharmaceuticals) for the treatment of idiopathic hypersomnia (IH). AZSTARYS competes with multiple methylphenidate products for attention deficit hyperactivity disorder (ADHD), including CONCERTA (J&J Innovative Medicines), QUELBREE (Supernus Pharmaceuticals, Inc.), QUILLIVANT XR and QUILLICHEW ER (Tris Pharma), RITALIN, FOCALIN, and FOCALIN XR (Novartis AG), METADATE CD (UCB SA), DAYTRANA (Noven Therapeutics, LLC), CONTEMPLA XR-ODT (Aytu BioScience, Inc.), JORNAY PM (Collegium Pharmaceutical Inc.), and ADHANSIA XR (Adlon Therapeutics). The company acknowledges competition from established and emerging companies with greater resources and capabilities in development, marketing, and regulatory approval processes.
: Niemann-Pick Disease Type C (NPC) is a rare, progressive genetic disorder characterized by the malfunction of lipid transport within cells, leading to a variety of debilitating symptoms and poor quality of life. Until recently, there has been a significant unmet medical need for effective therapeutic interventions for NPC. The approval and subsequent commercial availability of MIPLYFFA (arimoclomol) mark a momentous advancement in the management of this condition. This article highlights the therapeutic implications and accessibility of MIPLYFFA in the United States, ushering a new era in NPC patient care.Niemann-Pick Disease Type C is an autosomal recessive lysosomal storage disorder predominantly caused ...
In the ever-evolving landscape of clinical research and drug development, the spotlight is increasingly shining on therapies addressing rare sleep disorders. As the upcoming Sleep Europe 2024 conference approaches, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is poised to make significant waves in this domain. The company plans to present top-line data from its Phase 2 clinical trial of KP1077, a promising candidate aimed at tackling Idiopathic Hypersomnia (IH), a debilitating condition characterized by excessive daytime sleepiness.The Phase 2 trial results appear to affirm KP1077’s potential to provide clinically meaningful benefits for patients struggling with the symptoms of IH, which can severely impact qual...
At the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium, Zevra Therapeutics presented new clinical efficacy and safety data regarding two investigational drugs: Arimoclomol and OLPRUVA (sodium phenylbutyrate). The focus was primarily on Arimoclomol as a potential treatment for Niemann-Pick disease type C (NPC), a rare genetic disorder characterized by progressive neurological decline and systemic manifestations. Clinical Efficacy of ArimoclomolThe presentation highlighted various studies, including long-term and real-world evidence, indicating that Arimoclomol might significantly impact disease progression in patients with NPC. The data showed a clinically meaningful reducti...
The recent favorable vote by the FDA Advisory Committee regarding Arimoclomol represents a significant milestone in the quest for effective treatments for Niemann-Pick Disease Type C (NPC). This article interprets the implications of this decision, especially in the context of the upcoming Prescription Drug User Fee Act (PDUFA) action date set for September 21, 2024. We will explore the scientific background of Arimoclomol, the context of the advisory committee s findings, and the potential impact on its developing company. Understanding Niemann-Pick Disease Type C Niemann-Pick Disease Type C is a rare genetic disorder characterized by the accumulation of lipids in cells, leading to severe neurological and h...
Zevra Therapeutics Partners with Orsini for Enhanced Distribution of OLPRUVA® (Sodium Phenylbutyrate) for Urea Cycle Disorders Celebration, Fla. and Elk Grove Village, Ill., June 18, 2024 - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), an innovative pharmaceutical company dedicated to developing and commercializing transformative therapies for patients, and Orsini Specialty Pharmacy (Orsini), a market-leading independent provider of specialty pharmacy care, proudly announce that Orsini is now designated as the specialty pharmacy partner for the distribution and patient support of OLPRUVA® (sodium phenylbutyrate) for oral suspension. This proactive collaboration aims to streamline access to OLPRUVA® for pat...
Zevra Therapeutics, a leading pharmaceutical company dedicated to innovative solutions for sleep disorders, proudly revealed the positive final outcomes from its Phase 2 clinical trial of KP1077 at the prestigious SLEEP 2024 Annual Meeting. The remarkable results unveiled the significant potential of KP1077 as an efficacious treatment for individuals suffering from idiopathic hypersomnia, a debilitating sleep disorder.The eagerly anticipated phase of this trial focused on analyzing the tolerability and efficacy of KP1077, a novel therapeutic compound developed by Zevra Therapeutics. The company s commitment to addressing the unmet medical needs of patients with sleep disorders was vividly demonstrated by the...
Zevra Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company markets several therapies targeting specific medical conditions and faces competition from various branded and generic products. MIPLYFFA, approved for Niemann-Pick disease type C (NPC), competes with AQNEURSA marketed by IntraBio, Inc., as well as drug candidates adrabetadex from Mandos and cyclodextrin from Cyclo Therapeutics. OLPRUVA competes against phenylbutyrate products including RAVICTI (Amgen Inc.), PHEBURANE (Medunik USA), and authorized generics by Par and Lupin. KP1077 is positioned to compete with XYWAV (Jazz Pharmaceuticals) for the treatment of idiopathic hypersomnia (IH). AZSTARYS competes with multiple methylphenidate products for attention deficit hyperactivity disorder (ADHD), including CONCERTA (J&J Innovative Medicines), QUELBREE (Supernus Pharmaceuticals, Inc.), QUILLIVANT XR and QUILLICHEW ER (Tris Pharma), RITALIN, FOCALIN, and FOCALIN XR (Novartis AG), METADATE CD (UCB SA), DAYTRANA (Noven Therapeutics, LLC), CONTEMPLA XR-ODT (Aytu BioScience, Inc.), JORNAY PM (Collegium Pharmaceutical Inc.), and ADHANSIA XR (Adlon Therapeutics). The company acknowledges competition from established and emerging companies with greater resources and capabilities in development, marketing, and regulatory approval processes.
Sources:
Zevra Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Zevra Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Zevra Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
191.32 %